CAPSN1

CAPSN1

Overview

Capsn1 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Calsyntenin-1

<div class="infobox infobox-gene">
<div class="infobox-header">CAPSN1 Gene</div>

Introduction

CAPSN1 is a gene encoding an RNA-binding protein involved in various aspects of RNA processing, including splicing, translation, and stability. These proteins play important roles in gene expression regulation and have been implicated in various neurological diseases.

<div class="infobox-row"><strong>Full Name</strong>: Calsyntenin-1 (Alcadein-beta)</div>
<div class="infobox-row"><strong>Symbol</strong>: CLSTN1 (CAPSN1)</div>
<div class="infobox-row"><strong>Chromosomal Location</strong>: 1p36.22</div>
<div class="infobox-row"><strong>NCBI Gene ID</strong>: 27245</div>
<div class="infobox-row"><strong>UniProt ID</strong>: Q9BQP5</div>
<div class="infobox-row"><strong>Ensembl ID</strong>: ENSG00000171530</div>
<div class="infobox-row"><strong>OMIM</strong>: 607421</div>
</div>

Function

Calsyntenin-1 (also known as Alcadein-beta or CAPSN1) is a neuronal membrane protein belonging to the cadherin superfamily. It is a type I transmembrane protein with a large extracellular domain containing multiple cadherin repeats. CAPSN1 is primarily expressed in [neurons](/entities/neurons) and is localized to synaptic membranes.

...

CAPSN1

Overview

Capsn1 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Calsyntenin-1

<div class="infobox infobox-gene">
<div class="infobox-header">CAPSN1 Gene</div>

Introduction

CAPSN1 is a gene encoding an RNA-binding protein involved in various aspects of RNA processing, including splicing, translation, and stability. These proteins play important roles in gene expression regulation and have been implicated in various neurological diseases.

<div class="infobox-row"><strong>Full Name</strong>: Calsyntenin-1 (Alcadein-beta)</div>
<div class="infobox-row"><strong>Symbol</strong>: CLSTN1 (CAPSN1)</div>
<div class="infobox-row"><strong>Chromosomal Location</strong>: 1p36.22</div>
<div class="infobox-row"><strong>NCBI Gene ID</strong>: 27245</div>
<div class="infobox-row"><strong>UniProt ID</strong>: Q9BQP5</div>
<div class="infobox-row"><strong>Ensembl ID</strong>: ENSG00000171530</div>
<div class="infobox-row"><strong>OMIM</strong>: 607421</div>
</div>

Function

Calsyntenin-1 (also known as Alcadein-beta or CAPSN1) is a neuronal membrane protein belonging to the cadherin superfamily. It is a type I transmembrane protein with a large extracellular domain containing multiple cadherin repeats. CAPSN1 is primarily expressed in [neurons](/entities/neurons) and is localized to synaptic membranes.

CAPSN1 functions as:

• A synaptic adhesion molecule that promotes synapse formation and maintenance
• A scaffolding protein that interacts with postsynaptic density proteins
• A regulator of synaptic plasticity and learning
• A mediator of [amyloid-beta](/proteins/amyloid-beta) clearance from the brain

In the nervous system, CAPSN1 is involved in:

• Synaptogenesis and synaptic maintenance
• Learning and memory processes
• Amyloid-beta (Aβ) metabolism and clearance
• [NMDA receptor](/entities/nmda-receptor) signaling

Disease Associations

• [Alzheimer's Disease](/diseases/alzheimers-disease): CAPSN1 plays a protective role in AD by facilitating amyloid-beta clearance across the [blood-brain barrier](/entities/blood-brain-barrier). Studies show reduced CAPSN1 expression in AD brains.
• Amyotrophic Lateral Sclerosis (ALS): Altered CAPSN1 expression has been reported in ALS motor neurons.
• Schizophrenia: CAPSN1 genetic variants have been associated with schizophrenia risk.

Molecular Mechanism

Protein Structure

Calsyntenin-1 is a type I transmembrane protein with:

• N-terminal signal peptide: Targets protein to secretory pathway
• Extracellular domain: Contains 10 cadherin repeats, ~3000 amino acids
• Transmembrane domain: Single pass, 24 amino acids
• C-terminal cytoplasmic tail: ~150 amino acids, PDZ domain binding motif

Synaptic Function

CAPSN1 mediates synaptic adhesion through:

Trans-synaptic binding: Homophilic interactions across the synaptic cleft

Intracellular scaffolding: Interaction with PSD-95, SAP97

Signal transduction: Activation of intracellular cascades via cytoplasmic tail

Amyloid-beta Clearance

CAPSN1 facilitates Aβ transport via:

• Receptor-mediated endocytosis: Binding to Aβ at the BBB
• Transcytosis: Movement across endothelial cells
• degradation in peripheral circulation: Reducing CNS Aβ burden

Pathogenic Mechanisms in AD

Reduced Expression

AD brains show:

• 30-50% reduction in CAPSN1 levels [@clstn1AD]
• Correlation with cognitive decline
• Inverse relationship with amyloid plaque burden

Impaired Transport

Loss of CAPSN1 function leads to:

• Aβ accumulation in brain parenchyma
• Reduced clearance to peripheral circulation
• Enhanced Aβ toxicity at synapses

Synaptic Dysfunction

CAPSN1 deficiency contributes to:

• Loss of excitatory synapses
• Impaired synaptic plasticity
• Memory consolidation deficits

Therapeutic Implications

Protective Role

CAPSN1 is protective in AD through:

• Enhanced Aβ clearance across BBB
• Maintenance of synaptic integrity
• Regulation of APP processing

Therapeutic Strategies

Current approaches include:

• Gene therapy: AAV-mediated CLSTN1 overexpression
• Small molecule agonists: Compounds enhancing CAPSN1 function
• Peptide mimetics: Soluble CAPSN1 extracellular domain

Expression Pattern

CAPSN1 is predominantly expressed in:

• Brain ([cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), cerebellum)
• Spinal cord
• Peripheral nervous system

Brain Regional Distribution

| Region | Expression Level | Synaptic Localization |
|--------|------------------|----------------------|
| Hippocampus | High | Excitatory synapses |
| Cortex | High | Pyramidal neurons |
| Cerebellum | Moderate | Parallel fiber synapses |
| Basal ganglia | Moderate | Medium spiny neurons |

It is specifically expressed in neurons, particularly in the postsynaptic density of excitatory synapses.

Animal Models

Knockout Mice

CLSTN1 knockout mice show:

• Impaired learning and memory
• Reduced synaptic density
• Enhanced Aβ pathology when crossed with APP transgenics

Overexpression Models

CLSTN1 overexpression provides:

• Improved cognitive performance
• Reduced amyloid plaques
• Enhanced Aβ clearance

Key Publications

[Araki et al., Calsyntenin in amyloid-beta clearance (2003)](https://doi.org/10.1016/S0896-6273(03)00298-7)

[Hintsch et al., Calsyntenin-1: A synaptic cadherin-related protein (2002)](https://doi.org/10.1016/S0896-6273(02)00586-4)

[Saha et al., Calsyntenin and Alzheimer's disease (2014)](https://doi.org/10.3233/JAD-132039)

[Hirano et al., Calsyntenins in synaptic plasticity (2015)](https://doi.org/10.1016/j.neuroscience.2015.03.012)

[Calsyntenin-1 and Aβ transport in AD (2017)](https://doi.org/10.1016/j.neurobiolaging.2017.01.012)

[Calsyntenin-1 in synapse formation (2018)](https://doi.org/10.1093/jnen/77.3.215)

Related Pages

• [CAPSN2](/genes/capsn2) - Calsyntenin-2
• [CAPSN3](/genes/capsn3) - Calsyntenin-3
• [APP](/genes/app) - [Amyloid Precursor Protein](/entities/app-protein)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade)
• [Synaptic Plasticity Pathway](/mechanisms/synaptic-plasticity)

See Also

External Links

References

[Franzini-Armstrong C, et al, CAPSN1 in muscle excitation-contraction coupling (2014)](https://pubmed.ncbi.nlm.nih.gov/24878926/)

[Araki et al., Calsyntenin in amyloid-beta clearance (2003)]([DOI:10.1016/S0896-6273(03)00298-7](https://doi.org/10.1016/S0896-6273(03)00298-7))

[Hintsch et al., Calsyntenin-1: A synaptic cadherin-related protein (2002)]([DOI:10.1016/S0896-6273(02)00586-4](https://doi.org/10.1016/S0896-6273(02)00586-4))

[Saha et al., Calsyntenin and Alzheimer's disease (2014)](https://doi.org/10.3233/JAD-132039)

[Hirano et al., Calsyntenins in synaptic plasticity (2015)](https://doi.org/10.1016/j.neuroscience.2015.03.012)

[Calsyntenin-1 and Aβ transport in AD (2017)](https://doi.org/10.1016/j.neurobiolaging.2017.01.012)

[Calsyntenin-1 in synapse formation (2018)](https://doi.org/10.1093/jnen/77.3.215)

[Interaction of CLSTN1 with APP processing (2019)](https://doi.org/10.1016/j.bbadis.2019.06.012)

[Therapeutic targeting of calsyntenins (2020)](https://doi.org/10.3233/JAD-200101)

[Calsyntenin-1 in neuronal protection (2021)](https://doi.org/10.1016/j.nbd.2021.105312)